Application of a micropatterned cocultured hepatocyte system to predict preclinical and human-specific drug metabolism

Drug Metabolism and Disposition

Volumn 44, Issue 2, 2016, Pages 172-179

  Ballard, T Eric ^a   Wang, Shuai ^a,c   Cox, Loretta M ^a   Moen, Mark A ^a   Krzyzewski, Stacy ^b   Ukairo, Okechukwu ^b,d   Obach, R Scott ^a  

^a PFIZER INC   (United States)

^b Hepregen Corporation   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO ZONIPORIDE; 4 HYDROXY TOLBUTAMIDE; 4 OXO CARBAZERAN; ACECAINIDE; ACYL GLUCURONIDE; ACYLTRANSFERASE; ALDEHYDE OXIDASE; CARBAZERAN; CARBOXYTOLBUTAMIDE; CYTOCHROME P450 2C9; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A4; HYDRALAZINE; HYDROXYTOLBUTAMIDE; PROCAINAMIDE; SUNITINIB; TOLBUTAMIDE; TRIFLUOPERAZINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; ZONIPORIDE; DRUG;

ANIMAL CELL; ARTICLE; COCULTURE; CONTROLLED STUDY; DOG; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; MALE; METABOLIC RATE; MICROPATTERNED COCULTURED HEPATOCYTE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; ANIMAL; BIOLOGICAL MODEL; LIVER CELL; METABOLISM; PRECLINICAL STUDY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; COCULTURE TECHNIQUES; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HAPLORHINI; HEPATOCYTES; HUMANS; MALE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84958186127     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.066688     Document Type: Article

References (44)

1. Back DJ and Orme MLE (1989) Genetic factors influencing the metabolism of tolbutamide. Pharmacol Ther 44:147-155.
2. Ballard TE, Orozco CC, and Obach RS (2014) Generation of major human excretory and circulating drug metabolites using a hepatocyte relay method. Drug Metab Dispos 42: 899-902.
3. Beedham C, Bruce SE, Critchley DJ, al-Tayib Y, and Rance DJ (1987) Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 12:307-310.
4. Berry LM, Liu J, Colletti A, Krolikowski P, Zhao Z, and Teffera Y (2014) Species difference in glucuronidation formation kinetics with a selective mTOR inhibitor. Drug Metab Dispos 42:707-717.
5. Blaisdell J, Goldstein JA, and Bai SA (1998) Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26:278-283.
6. Breyer U and Schmalzing G (1977) Metabolism and disposition of trifluoperazine in the rat. I. A thin-layer chromatographic method for the measurement of trifluoperazine and its metabolites in rat tissues. Drug Metab Dispos 5:97-103.
7. Chan TS, Yu H, Moore A, Khetani SR, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024-2032.
8. Cui L, Takahashi S, Tada M, Kato K, Yamada Y, Kohri K, and Shirai T (2000) Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: results with 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) and 3,29-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity. Jpn J Cancer Res 91:52-58.
9. Dalvie DK, Khosla N, and Vincent J (1997) Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos 25:423-427.
10. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, and Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
11. Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, and Loi CM (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641-654.
12. Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach RS, Griffith LG, and Tannenbaum SR (2009) Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 5:1159-1174.
13. Diamond S, Boer J, Maduskuie TP, Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Speciesspecific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
14. Du Y, Wang J, Jia J, Song N, Xiang C, Xu J, Hou Z, Su X, Liu B, and Jiang T, et al. (2014) Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 14:394-403.
15. FDA (2006) Sutent (Sunitinib Malate) Drug Approval Package, http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2006/021938s000-021968s000-Stutent.cfm, accessed 21 November 2015.
16. FDA (2010) Guidance for Industry M3(R2). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246. pdf, accessed 21 November 2015.
17. Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. Drug Metab Dispos 32:295-304.
18. Gaertner HJ, Breyer U, and Liomin G (1974) Metabolism of trifluoperazine, fluphenazine, prochlorperazine and perphenazine in rats: in vitro and urinary metabolites. Biochem Pharmacol 23:303-311.
19. Gee SJ, Green CE, and Tyson CA (1984) Comparative metabolism of tolbutamide by isolated hepatocytes from rat, rabbit, dog, and squirrel monkey. Drug Metab Dispos 12:174-178.
20. Gómez-Lechón MJ, Castell JV, and Donato MT (2008) An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 4:837-854.
21. Graham MJ, Bell AR, Crewe HK, Moorcraft CL, Walker L, Whittaker EF, and Lennard MS (2003) mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 33:225-237.
22. Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, and Tanaka Y (2006) Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 27:133-139.
23. Kaku T, Ogura K, Nishiyama T, Ohnuma T, Muro K, and Hiratsuka A (2004) Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDPglucuronosyltransferase 1A4. Biochem Pharmacol 67:2093-2102.
24. Kaye B, Offerman JL, Reid JL, Elliott HL, and Hillis WS (1984) A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935-945.
25. Kerns EH and Di L (2008) Drug-Like Properties: Concepts, Structure Design, and Methods: From ADME to Toxicity Optimization, pp 329-347, Elsevier, Inc., Waltham, MA.
26. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
27. King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, and Tephly TR (1996) The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 332:92-100.
28. Kurosaki M, Bolis M, Fratelli M, Barzago MM, Pattini L, Perretta G, Terao M, and Garattini E (2013) Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression. Cell Mol Life Sci 70:1807-1830.
29. Minchin RF, Ilett KF, and Paterson JW (1978) Antiarrhythmic potency of procainamide and Nacetylprocainamide in rabbits. Eur J Pharmacol 47:51-56.
30. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, and Hada T (2001) Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16:745-753.
31. O'Connor D, Jones P, Chambers MS, Maxey R, Szekeres HJ, Szeto N, Scott-Stevens P, Macleod AM, BraunM, and Cato B (2006) Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABAA alpha5-subtype inverse agonist. Xenobiotica 36:315-330.
32. Pelkonen O and Raunio H (2005) In vitro screening of drug metabolism during drug development: can we trust the predictions? Expert Opin Drug Metab Toxicol 1:49-59.
33. Plant N (2004) Strategies for using in vitro screens in drug metabolism. Drug Discov Today 9: 328-336.
34. Smith CM, Nolan CK, EdwardsMA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, and Sahi J (2012) A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J Pharm Sci 101:3989-4002.
35. Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, and Kang P (2012) Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 40:539-555.
36. Taub ME, Ludwig-Schwellinger E, Ishiguro N, Kishimoto W, Yu H, Wagner K, and Tweedie D (2015) Sex-, species-, and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (m466/2) that degrades to 4-hydroxycrotonaldehyde, a reactive and cytotoxic species. Chem Res Toxicol PMID: 25489797 [published ahead of print].
37. Terao M, Kurosaki M, Barzago MM, Varasano E, Boldetti A, Bastone A, Fratelli M, and Garattini E (2006) Avian and canine aldehyde oxidases. Novel insights into the biology and evolution of molybdo-flavoenzymes. J Biol Chem 281:19748-19761.
38. Thomas RC and Ikeda GJ (1966) The metabolic fate of tolbutamide in man and in the rat. J Med Chem 9:507-510.
39. Trepanier LA, Ray K, Winand NJ, Spielberg SP, and Cribb AE (1997) Cytosolic arylamine Nacetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 54:73-80.
40. Troberg J, Järvinen E, Muniz M, Sneitz N, Mosorin J, Hagström M, and Finel M (2015) Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity. Drug Metab Dispos 43:107-118.
41. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
42. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, and Obach RS (2010) Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 38:1900-1905.
43. Xiao JF, Liu XJ, Liu GW, Yang XY, Xiao P, Hou XM, Wang HT, Tang JJ, Zhang YT, and Zhen C, et al. (2014) The metabolism of trifluoperazine (TFP) exhibits atypical kinetic behavior in both human liver microsomes (HLMs) and monkey liver microsomes (MyLM). Eur J Drug Metab Pharmacokinet 39:335-337.
44. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, and Plowchalk DR, et al. (2008) Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 65:680-692.